Breast cancer drug enhertu under the microscope: why do patients stop treatment?
NCT ID NCT06386263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study observed 22 adults with HER2-positive or HER2-low metastatic breast cancer who were taking trastuzumab deruxtecan (Enhertu) as part of routine care. Researchers tracked how many patients stopped treatment early or needed dose changes, and why. The goal is to provide real-world insights beyond clinical trials to help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (Enhertu)
What this could lead to
If successful, this study could help doctors and patients better understand how well trastuzumab deruxtecan works in everyday practice and why some people stop treatment.
What could go wrong
This is a small, completed observational study (22 people) that looks back at existing data, so it cannot prove cause and effect or predict outcomes for new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Oakville, Ontario, L6H1A7, Canada